Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Deal Watch: Takeda On A Deal Spree

Executive Summary

Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.

Advertisement

Related Content

Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances
Takeda To Press On With Core R&D Strategy Post-Shire
AstraZeneca’s Benralizumab Asthma Chase Gets Underway
AZ Partners Parkinson's Compound With Takeda
Takeda set to target EU market with Adcetris following CHMP nod
Takeda snags Intellikine in bid to bolster oncology pipeline

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124977

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel